[Induction of remission by sequential treatment with cytosine arabinoside (araC/high dose) and L-asparaginase].
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000627:therapeutic use
D003561:Cytarabine; D001215:Asparaginase; D011034:Podophyllotoxin
Inducción a la remisión con tratamiento secuencial de arabinósido de citosina (Ara-C/AD) y L-asparaginasa.